endometriosis. Female pelvic inflammatory disorders in other diseases classified elsewhere
Conditions
Interventions
Intervention 1: Agnugol tablet recipient at a dose of 3.2-4.8 mg once a day for 8 weeks. Intervention 2: placebo tablet recipient at the same dose and appearance once a day for eight weeks.
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 49 Years
Inclusion criteria
Inclusion criteria: Women with endometriosis whose disease has been diagnosed based on clinical symptoms and imaging (sonography) as well as previous documented evidence of endometriosis. Women with symptomatic endometriosis. Women who are in the age range of 18-49 years. They have not taken anti-inflammatory or hormonal drugs in the last three months. Don't have endometrial hypoplasia or neoplasia. Women who are married and sexually active.
Exclusion criteria
Exclusion criteria: Women who are allergic to medicinal plants, especially the Lamiaceae family. Women suffering from gallstones, jaundice due to biliary obstruction and acute biliary colic. Women with digestive diseases. Women who suffer from inflammatory diseases or diseases associated with immune system defects such as rheumatoid arthritis, lupus, multiple sclerosis, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life of endometriosis patients. Timepoint: before investigation and 8 weeks after investigation. Method of measurement: questionnaire 30-EHP.;Symptoms of pelvic pain and gynecology. Timepoint: before investigation and 8 weeks after investigation. Method of measurement: questionnaire ENDOPAIN-4D. | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain. Timepoint: the first 3 days of the next 3 menstrual cycles. Method of measurement: VAS ruler. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElnaz Shaseb
Tabriz University of Medical Sciences
Outcome results
None listed